An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Items 101–200 of 1,001
High throughput physiological screening of iPSC-derived cardiomyocytes for drug development
del Álamo, J. C., Lemons, D., Serrano, R., Savchenko, A., Cerignoli, F., Bodmer, R., & Mercola, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.003 · Cited by 134
Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
Bayliss, M. K., Butler, J., Feldman, P. L., Green, D. V. S., Leeson, P. D., Palovich, M. R., & Taylor, A. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.007 · Cited by 134
Self-citationA map of the amine–carboxylic acid coupling system
Mahjour, B. A., Shen, Y., Liu, W., & Cernak, T. (2020) · Nature · doi:10.1038/s41586-020-2142-y · Cited by 134
Singh, N., Marets, C., Boudon, J., Millot, N., Saviot, L., & Maurizi, L. (2021) · Nanoscale Advances · doi:10.1039/d0na00863j · Cited by 116
An Overview of Organs-on-Chips Based on Deep Learning
Li, J., Chen, J., Bai, H., Wang, H., Hao, S., Ding, Y., Peng, B., Zhang, J., Li, L., & Huang, W. (2022) · Research · doi:10.34133/2022/9869518 · Cited by 134
Mignani, S. M., Rodrigues, J., Tomás, H., Jalal, R., Singh, P. P., Majoral, J., & Vishwakarma, R. A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.010 · Cited by 133
Today’s Challenges to De-Risk and Predict Drug Safety in Human “Mind-the-Gap”
Weaver, R. J., & Valentin, J.-P. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfy270 · Cited by 119
Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.023 · Cited by 118
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies
Norman, B. H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00524 · Cited by 118
Ivanenkov, Y. A., Zagribelnyy, B. A., & Aladinskiy, V. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00004 · Cited by 121
Meta Learning With Graph Attention Networks for Low-Data Drug Discovery
Lv, Q., Chen, G., Yang, Z., Zhong, W., & Chen, C. Y.-C. (2024) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2023.3250324 · Cited by 106
Influence of artificial intelligence in modern pharmaceutical formulation and drug development
Ali, K. A., Mohin, S., Mondal, P., Goswami, S., Ghosh, S., & Choudhuri, S. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00625-1 · Cited by 132
Kenna, J. G., Taskar, K. S., Battista, C., Bourdet, D. L., Brouwer, K. L. R., Brouwer, K. R., Dai, D., Funk, C., Hafey, M. J., Lai, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1222 · Cited by 123
Irreproducibility in Preclinical Biomedical Research: Perceptions, Uncertainties, and Knowledge Gaps
Jarvis, M. F., & Williams, M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.12.001 · Cited by 129
“Reproducibility in Biomedical Research Reports of the inability to reproduce findings in preclinical biomedical research are considered by many to be a major contributory factor to the lack of efficiency and productivity in drug development, as reflected in the disconnect between research funding and new drug approval…”
BackgroundInfluentialApplications of tumor chip technology
Hachey, S. J., & Hughes, C. C. W. (2018) · Lab on a Chip · doi:10.1039/c8lc00330k · Cited by 128
Modeling Physico-Chemical ADMET Endpoints with Multitask Graph Convolutional Networks
Montanari, F., Kuhnke, L., Ter Laak, A., & Clevert, D.-A. (2019) · Molecules · doi:10.3390/molecules25010044 · Cited by 115
Generative Network Complex for the Automated Generation of Drug-like Molecules
Gao, K., Nguyen, D. D., Tu, M., & Wei, G. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00599 · Cited by 128
The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS)
Boddy, S. L., Giovannelli, I., Sassani, M., Cooper-Knock, J., Snyder, M. P., Segal, E., Elinav, E., Barker, L. A., Shaw, P. J., & McDermott, C. J. (2021) · BMC Medicine · doi:10.1186/s12916-020-01885-3 · Cited by 127
Image-based high-content screening in drug discovery
Lin, S., Schorpp, K., Rothenaigner, I., & Hadian, K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.001 · Cited by 124
Strategies for 3D bioprinting of spheroids: A comprehensive review
Banerjee, D., Singh, Y. P., Datta, P., Özbolat, V., O'Donnell, A., Yeo, M., & Ozbolat, I. T. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121881 · Cited by 124
Ahmad, I. I., Kuznetsov, A. E., Pirzada, A. S., Alsharif, K. F., Daglia, M., & Khan, H. Z. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1145974 · Cited by 124
Synthesis and anticancer activity of novel water soluble benzimidazole carbamates
Cheong, J. E., Zaffagni, M., Chung, I., Xu, Y., Wang, Y., Jernigan, F. E., Zetter, B. R., & Sun, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.037 · Cited by 122
Sala, L., Bellin, M., & Mummery, C. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13577 · Cited by 121
Challenges in Translational Development of Pharmaceutical Cocrystals
Kale, D. P., Zode, S. S., & Bansal, A. K. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.10.021 · Cited by 121
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
Young, R. J., & Leeson, P. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00180 · Cited by 121
Self-citationMessina, A., Luce, E., Hussein, M., & Dubart-Kupperschmitt, A. (2020) · Cells · doi:10.3390/cells9020420 · Cited by 107
Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety
He, R., Finan, B., Mayer, J. P., & DiMarchi, R. D. (2019) · Molecules · doi:10.3390/molecules24101855 · Cited by 118
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline
Cornet, C., Donato, V. D., & Terriente, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00703 · Cited by 117
Breakthroughs and Applications of Organ-on-a-Chip Technology
Koyilot, M. C., Natarajan, P., Hunt, C. R., Sivarajkumar, S., Roy, R., Joglekar, S. S., Pandita, S., Tong, C. W.-C., Marakkar, S., Subramanian, L., et al. (2022) · Cells · doi:10.3390/cells11111828 · Cited by 117
Subbaiah, M. A. M., Rautio, J., & Meanwell, N. A. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00957a · Cited by 115
Disciplined approach to drug discovery and early development
Plenge, R. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2608 · Cited by 101
Automation and data-driven design of polymer therapeutics
Upadhya, R., Kosuri, S., Tamasi, M., Meyer, T. A., Atta, S., Webb, M. A., & Gormley, A. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.009 · Cited by 113
The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
Edueng, K., Mahlin, D., & Bergström, C. A. S. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2174-7 · Cited by 110
Predicting and Experimentally Validating Hot-Spot Residues at Protein–Protein Interfaces
Ibarra, A. Á., Bartlett, G. J., Hegedüs, Z., Dutt, S., Hóbor, F., Horner, K. A., Hetherington, K., Spence, K., Nelson, A. S., Edwards, T. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00560 · Cited by 109
Edmondson, S. D., Zhu, C. G., Kar, N. F., Salvo, J. D., Nagabukuro, H., Sacre-Salem, B., Dingley, K. H., Berger, R., Goble, S. D., Morriello, G. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01372 · Cited by 108
ADMETopt: A Web Server for ADMET Optimization in Drug Design via Scaffold Hopping
Yang, H., Sun, L., Wang, Z., Li, W., Liu, G., & Tang, Y. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00532 · Cited by 106
The promises of quantitative systems pharmacology modelling for drug development
Knight-Schrijver, V. R., Chelliah, V., Cucurull-Sanchez, L., & Le Novère, N. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.002 · Cited by 97
Lei, T., Sun, H., Kang, Y., Zhu, F., Liu, H., Zhou, W., Wang, Z., Li, D., Li, Y., & Hou, T. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00631 · Cited by 105
Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects
Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P., & Ward, L. D. (2019) · Nature Communications · doi:10.1038/s41467-019-09407-3 · Cited by 101
Log D Contributions of Substituents Commonly Used in Medicinal Chemistry
Landry, M. L., & Crawford, J. J. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00489 · Cited by 105
Artificial intelligence for compound pharmacokinetics prediction
Obrezanova, O. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102546 · Cited by 74
Shameer, K., Glicksberg, B. S., Hodos, R., Johnson, K. W., Badgeley, M. A., Readhead, B., Tomlinson, M. S., O’Connor, T., Miotto, R., Kidd, B. A., et al. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbw136 · Cited by 103
Ahmad, I. I., Khan, H. Z., & Serdaroğlu, G. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107861 · Cited by 102
ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish
Cornet, C., Calzolari, S., Prieto, R. M., Dyballa, S., van Doornmalen, E. J. P., Rutjes, H., Savy, T., D’Amico, D., & Terriente, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040864 · Cited by 102
Trends in small molecule drug properties: A developability molecule assessment perspective
Agarwal, P., Huckle, J. E., Newman, J., & Reid, D. L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103366 · Cited by 101
In Silico Prediction of Compounds Binding to Human Plasma Proteins by QSAR Models
Sun, L., Yang, H., Li, J., Wang, T., Li, W., Liu, G., & Tang, Y. (2017) · ChemMedChem · doi:10.1002/cmdc.201700582 · Cited by 101
Network-based technologies for early drug discovery
Fotis, C. K., Antoranz, A., Hatziavramidis, D., Sakellaropoulos, T., & Alexopoulos, L. G. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.12.001 · Cited by 101
Knowledge-based BERT: a method to extract molecular features like computational chemists
Wu, Z., Jiang, D., Wang, J., Zhang, X., Du, H., Pan, L., Hsieh, C., Cao, D., & Hou, T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac131 · Cited by 99
Self-citationUsing human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 99
Safety pharmacology investigations on the nervous system: An industry survey
Authier, S., Arezzo, J. C., Delatte, M. S., Kallman, M. J., Markgraf, C. G., Paquette, D., Pugsley, M. K., Ratcliffe, S., Redfern, W. S., Stevens, J., et al. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.06.001 · Cited by 99
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity
Lauschke, V., & Ingelman-Sundberg, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101714 · Cited by 88
Alberga, D., Gambacorta, N., Trisciuzzi, D., Ciriaco, F., Amoroso, N., & Nicolotti, O. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00517 · Cited by 97
Sutherland, J. J., Webster, Y., Willy, J. A., Searfoss, G. H., Goldstein, K. M., Irizarry, A. R., Hall, D. G., & Stevens, J. L. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.17 · Cited by 97
Fluorescent ligands: Bringing light to emerging GPCR paradigms
Soave, M., Briddon, S. J., Hill, S. J., & Stoddart, L. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14953 · Cited by 96
Current status and future directions of high-throughput ADME screening in drug discovery
Shou, W. Z. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.05.004 · Cited by 96
HobPre: accurate prediction of human oral bioavailability for small molecules
Wei, M., Zhang, X., Pan, X., Wang, B., Ji, C., Qi, Y., & Zhang, J. Z. H. (2022) · Journal of Cheminformatics · doi:10.1186/s13321-021-00580-6 · Cited by 96
Harlow, P. H., Perry, S. J., Widdison, S., Daniels, S. A., Bondo, E., Lamberth, C., Currie, R. A., & Flemming, A. J. (2016) · Scientific Reports · doi:10.1038/srep22965 · Cited by 93
Parasrampuria, D. A., Benet, L. Z., & Sharma, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0204-y · Cited by 93
Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
Silva, M. C., & Haggarty, S. J. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14012 · Cited by 83
The compromise of virtual screening and its impact on drug discovery
Slater, O., & Kontoyianni, M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1604677 · Cited by 92
Liquid-based three-dimensional tumor models for cancer research and drug discovery
Ham, S. L., Joshi, R., Thakuri, P. S., & Tavana, H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216643772 · Cited by 91
Stegemann, S., Moreton, C., Svanbäck, S., Box, K. J., Motte, G., & Paudel, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103344 · Cited by 91
Inventing new therapies without reinventing the wheel: the power of drug repurposing
Papapetropoulos, A., & Szabó, C. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14081 · Cited by 91
Drug–Target Association Kinetics in Drug Discovery
IJzerman, A. P., & Guo, D. M. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.04.004 · Cited by 90
Multiobjective de novo drug design with recurrent neural networks and nondominated sorting
Yasonik, J. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00419-6 · Cited by 77
Novel p38α MAP kinase inhibitors identified from yoctoReactor DNA-encoded small molecule library
Petersen, L. K., Blakskjær, P., Chaikuad, A., Christensen, A. B., Dietvorst, J., Holmkvist, J., Knapp, S., Kořínek, M., Larsen, L. K., Pedersen, A. E., et al. (2016) · MedChemComm · doi:10.1039/c6md00241b · Cited by 84
Harnessing the Properties of Natural Products
Boufridi, A., & Quinn, R. J. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105029 · Cited by 90
Plummer, S. M., Wallace, S., Ball, G., Lloyd, R., Schiapparelli, P. V., Quiñones‐Hinojosa, A., Härtung, T., & Pamies, D. (2019) · Scientific Reports · doi:10.1038/s41598-018-38130-0 · Cited by 89
Engineered tissues and strategies to overcome challenges in drug development
Khalil, A. S., Jaenisch, R., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.012 · Cited by 89
Artificial intelligence in the pharmaceutical sector: current scene and future prospect
Kalyane, D., Sanap, G., Paul, D., Shenoy, S., Anup, N., Polaka, S., Tambe, V., & Tekade, R. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814455-8.00003-7 · Cited by 88
Quantum Machine Learning Predicting ADME-Tox Properties in Drug Discovery
Bhatia, A. S., Saggi, M. K., & Kais, S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01079 · Cited by 88
Public perception of laboratory animal testing: Historical, philosophical, and ethical view
Petetta, F., & Ciccocioppo, R. (2020) · Addiction Biology · doi:10.1111/adb.12991 · Cited by 86
Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation
Parvez, M. M., Basit, A., Jariwala, P. B., Gáborik, Z., Kis, E., Heyward, S. A., Redinbo, M. R., & Prasad, B. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000476 · Cited by 86
Tissue Chips in Space: Modeling Human Diseases in Microgravity
Low, L. A., & Giulianotti, M. A. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2742-0 · Cited by 85
Application of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
Acker, T. V., Malderen, S. J. M. V., van Heerden, M., McDuffie, J. E., Cuyckens, F., & Vanhaecke, F. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.10.014 · Cited by 85
Optimizing drug discovery by Investigative Toxicology: Current and future trends
Beilmann, M., Boonen, H., Czich, A., Dear, G., Hewitt, P., Mow, T., Newham, P., Oinonen, T., Pognan, F., Roth, A., et al. (2018) · ALTEX · doi:10.14573/altex.1808181 · Cited by 85
Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development
Wang, L., Phan, D.-D. K., Zhang, J., Ong, P.-S., Thuya, W. L., Soo, R. A., Wong, A. L.-A., Yong, W. P., Lee, S. C., Ho, P. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8316 · Cited by 83
An Improved Free Energy Perturbation FEP+ Sampling Protocol for Flexible Ligand-Binding Domains
Fratev, F., & Sirimulla, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-53133-1 · Cited by 83
Multi-Compartment 3D-Cultured Organ-on-a-Chip: Towards a Biomimetic Lymph Node for Drug Development
Shanti, A., Samara, B., Abdullah, A., Hallfors, N., Accoto, D., Sapudom, J., Alatoom, A., Teo, J. C. M., Danti, S., & Stefanini, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050464 · Cited by 83
Human iPSC modeling of heart disease for drug development
Hnatiuk, A. P., Briganti, F., Staudt, D., & Mercola, M. A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.016 · Cited by 82
A complex game of hide and seek: the search for new antifungals
Ngo, H., Garneau‐Tsodikova, S., & Green, K. D. (2016) · MedChemComm · doi:10.1039/c6md00222f · Cited by 82
Converting extracellular vesicles into nanomedicine: loading and unloading of cargo
Joshi, B. S., Ortíz-Rios, D., & Zuhorn, I. S. (2021) · Materials Today Nano · doi:10.1016/j.mtnano.2021.100148 · Cited by 81
Spruill, M. L., Maletić‐Savatić, M., Martin, H., Li, F., & Liu, X. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115080 · Cited by 81
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 81
Arzi, R. S., & Sosnik, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.012 · Cited by 81
Falcón-Cano, G., Molina, C. G., & Cabrera‐Pérez, M. Á. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00019 · Cited by 80
Dirven, H. A. A. M., Vist, G. E., Bandhakavi, S., Mehta, J., Fitch, S., Pound, P., Ram, R., Kincaid, B., Leenaars, C. H. C., Chen, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85708-2 · Cited by 80
Daina, A., Blatter, M.-C., Gerritsen, V. B., Palagi, P. M., Marek, D., Xénarios, I., Schwede, T. F., Michielin, O. A., & Zoete, V. (2017) · Journal of Chemical Education · doi:10.1021/acs.jchemed.6b00596 · Cited by 80
Guiding the rational design of biocompatible metal-organic frameworks for drug delivery
Menon, D., & Fairen‐Jiménez, D. (2025) · Matter · doi:10.1016/j.matt.2025.101958 · Cited by 79
Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms
Pang, L., Sager, P., Yang, X., Shi, H., Sannajust, F., Brock, M., Wu, J. C., Abi-Gerges, N., Lyn-Cook, B., Berridge, B. R., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315378 · Cited by 73
The Ascendance of Microphysiological Systems to Solve the Drug Testing Dilemma
Dehne, E.-M., Hasenberg, T., & Marx, U. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0002 · Cited by 68
Therapeutic targeting of senescent cells in the CNS
Riessland, M., Ximerakis, M., Jarjour, A. A., Zhang, B., & Orr, M. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01033-z · Cited by 77
Species-Dependent Mechanisms of Cardiac Arrhythmia: A Cellular Focus
Edwards, A. G., & Louch, W. E. (2017) · Clinical Medicine Insights Cardiology · doi:10.1177/1179546816686061 · Cited by 77
Introduction to the EQIPD quality system
Bespalov, A., Bernard, R., Gilis, A., Gerlach, B., Guillén, J., Castagné, V., Lefevre, I. A., Ducrey, F., Monk, L., Bongiovanni, S., et al. (2021) · eLife · doi:10.7554/elife.63294 · Cited by 76
Schütz, C., Ho, D., Hamed, M. M., Abdelsamie, A. S., Röhrig, T., Herr, C., Kany, A. M., Rox, K., Schmelz, S., Siebenbürger, L., et al. (2021) · Advanced Science · doi:10.1002/advs.202004369 · Cited by 76
Elbouzidi, A., Ouassou, H., Aherkou, M., Kharchoufa, L., Meskali, N., Baraich, A., Mechchate, H., Bouhrim, M., Idir, A., Hano, C., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15091156 · Cited by 76
Saddala, M. S., & Hu, H. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1965-5 · Cited by 76
Stem Cells for Next Level Toxicity Testing in the 21st Century
Fritsche, E., Haarmann‐Stemmann, T., Kapr, J., Galanjuk, S., Hartmann, J., Mertens, P. R., Kämpfer, A. A. M., Schins, R. P. F., Tigges, J., & Koch, K. (2021) · Small · doi:10.1002/smll.202006252 · Cited by 75
Wang, J., Sun, D., Huang, L., Wang, S., & Jin, Y. H. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8532940 · Cited by 75
Self-citation
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.